KIRSTY (water) by Biocon is insulin, including insulin aspart products, is the regulation of glucose metabolism. Approved for glycemic control in adults. First approved in 2025.
Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
KIRSTY (water) is a Biocon-sponsored insulin analog injection approved July 2025 for glycemic control in adults with diabetes. It works by regulating glucose metabolism through stimulation of peripheral glucose uptake and inhibition of hepatic glucose production. The product is entering launch phase as a solution-based injectable formulation.
Early-stage launch with moderate competitive pressure (30%) suggests growing commercial infrastructure needs and field team expansion opportunities.
insulin, including insulin aspart products, is the regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis,…
Insulin Analog
Effects of Increased Water Intake on Hormonal Response, Hydration Status, and Physical Function in Low-drinking Older Adults
A Research Study Looking at the Effect of Timing of Meal After Dosing and Water Volume at Dosing on How the Medicine Zenagamtide is Taken up by the Body of Participants With Overweight or Obesity
WATER IV PCa (AS Sub-study)
Wastewater Surveillance for Carbapenem-Resistant Organism Outbreak Prediction in a Chinese Tertiary Hospital
Rural Water Filtration and Health Study
Worked on KIRSTY at Biocon? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moKIRSTY offers limited career momentum given zero linked job postings and a crowded, commoditized market with mature competitors. Career progression will depend on Biocon's market penetration success and team scaling, but differentiation challenges and competitive saturation suggest modest upside.